SCHEMBL18571687

SCHEMBL18571687

CSc1ncnn2c(C3CCC(CO)O3)ccc12

nearest known ligand 0.37

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ CYP2A6 P11509 1/20 0.37
▸ TP53 P04637 1/20 0.30
▸ SMN1; SMN2 Q16637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23584545 1.00 CYP2A6 (0.37) CYP2A6TP53SMN1; SMN2
SCHEMBL19344220 0.82 CYP2A6 (0.39) CYP2A6
SCHEMBL18667150 0.82 CYP2A6 (0.39) CYP2A6
SCHEMBL4970560 0.82 CYP2A6 (0.39) CYP2A6
SCHEMBL19343962 0.82 CYP2A6 (0.39) CYP2A6
SCHEMBL20834954 0.81 MAP4K4 (0.37) CYP2A6
SCHEMBL25948690 0.80 HRH4 (0.45) —
SCHEMBL23584542 0.80 HRH4 (0.45) —
SCHEMBL23959828 0.80 CYP2A6 (0.38) CYP2A6
SCHEMBL23584697 0.80 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4219496-A1 NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS JANSSEN Pharmaceutica NV (BE) 2023-08-02 — — EP disclosed
EP-3341368-B1 NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2021-10-06 — — EP disclosed
EP-3426664-B1 SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2021-06-30 — — EP disclosed
WO-2017153186-A1 SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2017-09-14 — — WO disclosed
WO-2017032840-A1 NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2017-03-02 — — WO disclosed
Send feedback